Caristo Diagnostics
Caristo Diagnostics, founded in 2018 by cardiologists from the University of Oxford, is a company revolutionizing cardiac disease diagnosis and treatment. Their core technology, CaRi-Heart®, extracts previously invisible information from routine cardiac CT scans to visualize and quantify coronary inflammation. This enables more comprehensive risk assessment, leading to personalized treatments and improved prevention strategies. The company's mission is to transform health outcomes through clinical and scientific innovation. CaRi-Heart® has received CE mark and is available in Europe, the UK, and Australia, with future products planned for stroke and diabetes risk prediction. Caristo has partnered with Agepha Pharma to raise awareness and provide education on the role of inflammation in cardiovascular disease, supporting clinical research with CaRi-Heart® and LODOCO®.
Caristo Diagnostics
Caristo Diagnostics, founded in 2018 by cardiologists from the University of Oxford, is a company revolutionizing cardiac disease diagnosis and treatment. Their core technology, CaRi-Heart®, extracts previously invisible information from routine cardiac CT scans to visualize and quantify coronary inflammation. This enables more comprehensive risk assessment, leading to personalized treatments and improved prevention strategies. The company's mission is to transform health outcomes through clinical and scientific innovation. CaRi-Heart® has received CE mark and is available in Europe, the UK, and Australia, with future products planned for stroke and diabetes risk prediction. Caristo has partnered with Agepha Pharma to raise awareness and provide education on the role of inflammation in cardiovascular disease, supporting clinical research with CaRi-Heart® and LODOCO®.
